Short-acting beta-agonist research: A perspective

Canadian Respiratory Journal

Volumn 8, Issue 5, 2001, Pages 349-355

  Sears, M R ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Asthma; Beta agonist; Morbidity; Mortality; Research; Severity

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; NEDOCROMIL; PLACEBO; PREDNISONE; SALBUTAMOL; THEOPHYLLINE;

ARTICLE; ASTHMA; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RESEARCH; DRUG USE; DRUG WITHDRAWAL; HUMAN; INHALER; MORBIDITY; MORTALITY; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; RISK FACTOR; SIDE EFFECT;

EID: 0035202851     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/987151     Document Type: Article

References (30)

1. Asthma mortality in New Zealand: A two year national study
2. Lessons from the national asthma mortality study: Circumstances surrounding death
3. 75 deaths in asthmatics prescribed home nebulisers
4. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between budesonide and terbutaline
5. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma
6. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline
7. Regular versus symptomatic aerosol bronchodilator treatment of asthma
8. Regular inhaled beta-agonist treatment in bronchial asthma
9. Regular inhaled β-agonist in asthma: Effect on exacerbations and lung function
10. A new index of prognostic severity for chronic asthma
11. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: Case-control study
12. The β2-agonist controversy. Observations, explanations and relationship to asthma epidemiology
13. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81
14. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: A further case-control study
15. The use of β-agonists and the risk of death and near death from asthma
16. A cohort analysis of excess mortality in asthma and the use of inhaled beta agonists
17. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline
18. Cardiovascular effects of fenoterol under conditions of hypoxaemia
19. Regular inhaled salbutatmol and airway responsiveness to allergen
20. Regular use of inhaled albuterol and the allergen-induced late asthmatic response
21. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction
22. Risk of severe life threatening asthma and β-agonist type: An example of confounding by severity
23. 2 agonists and their antagonists
24. Trends in sales of drugs for asthma in New Zealand, Australia and the United Kingdom 1975-81
25. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed
26. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
27. Bronchodilators and bronchial hyperresponsiveness
28. Epidemiological trends in asthma
29. The environment and disease: Association or causation?